Europe Minimal Residual Disease Testing Market Size, Share & Industry Trends Analysis Report By Application (Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others), By End User, By Technology, By Country and Growth Forecast, 2022 - 2028
The Europe Minimal Residual Disease Testing Market would witness market growth of 14.0% CAGR during the forecast period (2022-2028).
Barriers to the application of biomarker testing alternatives are expanding along with their usage in the treatment of specific cancers. Lack of knowledge about how biomarker testing functions and what impact it can have on choosing the most effective cancer treatment options underlies these hurdles. Additionally, the morphologic evaluation of complete remission (presence of 5% or fewer blasts in bone marrow) is insufficient to detect residual malignant cells.
Conversely, MRD tests produce results with higher degrees of disease detection sensitivity. Monitoring of MRD gives a technique to precisely evaluate the early therapeutic efficacy and detect relapse in individuals with acute lymphoblastic leukemia (ALL).
The abnormal immunophenotypes’ detection by flow cytometry, PCR amplification of fusion transcripts, and PCR amplification of antigen-receptor genes are well-established techniques for studying MRD. In addition, it is widely known that there is a significant association between MRD concentrations and the probability of relapse in pediatric ALL.
The usage of minimal residual disease testing has gained a significant position in this region because of its advance prognostic importance for producing results and increasing the adoption of MRD diagnostics possibilities in treatment stratification. Therefore, the need for methodology standardization and terminology harmonization has increased exponentially in the region. Additionally, the prevalence of cancer is rising quickly in the region. Approximately 2.7 million people in the European Union received a diagnosis of the illness in 2020, and about 1.3 million people passed away as a result, according to the European Commission.
The Germany market dominated the Europe Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $181.2 million by 2028.The UK market is experiencing a CAGR of 13.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 14.8% during (2022 - 2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End User, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Scope of the Study
Market Segments covered in the Report:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook